Healthtech Startups

Cuvris builds specialty-focused AI agents that automate healthcare practice operations, including referral triage, patient intake, qualification, scheduling, and clinical documentation. It serves care teams and medical practices to reduce administrative workload, improve chart accuracy, and lower claim denials.

1 investor

CV6 Therapeutics develops investigational cancer therapies designed for combination use with established standards of care, with a lead program (CV6-168) intended to enhance the activity of 5-fluorouracil and other thymidylate synthase-targeted therapies. The company is advancing CV6-168 through Phase 1a clinical development.

1 investor

CvergenX develops the precisionRT Dose (pRTD) platform, which uses gene-expression biomarkers (RSI) and the Genomic Adjusted Radiation Dose (GARD) metric to predict tumor radiosensitivity and personalize radiotherapy dosing. It provides predictive analytics for biologically guided radiation oncology, serving clinical and research use in cancer treatment.

1 investor

CVS Health is a health care company that connects people to care through insurance plans, retail and specialty pharmacies, prescription delivery, walk-in appointments, and a pharmacy benefit manager. It serves individuals and families in the United States, offering services to manage chronic conditions, mental and physical well-being, and access to affordable medications.

1 investor

CWS provides hygiene, protective workwear, cleanroom, fire protection, and healthcare products and services for businesses. The company operates across five business divisions focused on workplace safety, health, and sustainability solutions.

1 investor

Cyberpsyc is a Canadian provider of online mental health support delivered through computerized cognitive behavioral therapy. Its interactive, self-directed programs address stress, anxiety and depression, with a focus on student users.

1 investor

Cyclarity Therapeutics develops drugs based on cyclodextrin derivatives to treat atherosclerosis by removing arterial plaque, targeting the non-degradable cholesterol that accumulates in arterial wall cells. The company aims to provide a preventive therapy for age-related cardiovascular conditions such as heart attack and stroke.

1 investor

Cyclops Medtech develops a portfolio of vestibular diagnostic and therapy products—including videonystagmography (VNG/VOG), video head impulse testing (vHIT), dynamic visual acuity, stabilometry platforms, VR-based vestibular rehabilitation, and a smart balance board—to diagnose and treat dizziness and balance disorders. Its tools serve clinicians across neurotology, neurology, physiotherapy, audiology, and ophthalmology.

1 investor

Cyclotek manufactures and distributes PET radiopharmaceuticals and radioactive medical devices for hospitals, research institutions, and clinical partners across Australia and New Zealand. The company provides GMP manufacturing, supply chain coordination, and translational support to enable molecular imaging diagnostics and therapy.

1 investor

CyDen develops clinically proven light-based hair and skin wellness devices, transforming professional aesthetic technologies into safe, effective at-home consumer products. The company serves consumers seeking at-home beauty treatments and wellness solutions.

1 investor

Captisol is a pharmaceutical-grade sulfobutylether beta-cyclodextrin (SBECD), a derivatized beta cyclodextrin used to solubilize and stabilize difficult-to-deliver molecules across routes such as parenteral, oral, ophthalmic, nasal, and inhalation. Made by CyDex Pharmaceuticals (a Ligand company), it is used in approved therapeutics including remdesivir and carfilzomib, and is also explored for consumer health, supplements, and personal care products.

1 investor

CyGenica develops a targeted intracellular drug delivery technology, the GEENIE platform, to deliver therapeutic molecules into cells more safely and efficiently. Its work focuses on treatments for oncology and rare genetic diseases, serving biopharmaceutical companies developing therapies.

1 investor

Cygnus Med develops the EndoSphinx, an endovascular access system that provides continuous arterial blood pressure monitoring while eliminating blood loss and preventing clotting inside the guiding catheter during endovascular procedures. The device is aimed at clinicians performing endovascular interventions.

1 investor

Cynapsus is a specialty central nervous system pharmaceutical company developing a fast-acting, sublingual thin film for on-demand management of OFF episodes in Parkinson's disease patients. It is preparing to commercialize the therapy.

1 investor

CynosBio develops and commercializes regenerative medicine products, including cell-based treatments for cartilage damage, joint disorders, and liver disease. The company is based in Japan and pursues global expansion, particularly in the United States.

1 investor

1 investor

Develops regenerative therapy for persistent smell loss, currently in Phase 2 clinical trials.

1 investor

Cyrano Therapeutics is a clinical-stage regenerative medicine company developing CYR-064, a nasal therapy for post-viral smell loss (hyposmia) and associated loss of taste. It serves patients with anosmia and is advancing its lead candidate through clinical trials toward Phase 3.

1 investor

Cyrano Video provides subscription-based video production services combining customized hardware, software, and editorial support for healthcare organizations. The platform enables clients to produce video content at scale across multiple formats—in-studio, at-desk, and mobile—for enhanced internal communication, patient engagement, and personalized outreach.

1 investor

CyrenCare provides digital patient intake software that captures clinical information through customizable forms and generates clinician-friendly reports for healthcare providers. The platform supports multilingual service delivery.

1 investor

cystetic Medicines is a drug development company creating an inhaled dry-powder therapy based on an FDA-approved antifungal compound to treat cystic fibrosis, targeting the roughly 10% of patients not helped by existing modulators. The company focuses on accessible, scalable treatment using aerodynamically engineered nanoparticle delivery.

1 investor

Cyta Therapeutics develops polymer-based nanogel therapeutics (IntelliGels) to treat obesity, NASH, type 2 diabetes, and metabolic disorders. The company's lead program, Cyta-001, is a liver-targeted drug delivery system encapsulating a thyroid hormone receptor agonist for metabolic disease management.

1 investor

CytoAgents is a clinical-stage biopharmaceutical company developing therapies for the life-threatening symptoms of Cytokine Release Syndrome (CRS), an immune overreaction causing systemic inflammation. It is led by a team of drug development experts and a scientific advisory board focused on immunology and clinical drug development.

1 investor

Cytodyme builds software for regulatory and quality teams at life science companies to manage post-market reporting, literature reviews, documentation, audits, and submissions. The platform consolidates data from disconnected systems to reduce administrative burden for regulated life science and biotech teams.

1 investor